ADMA Biologics (ADMA) Projected to Post Earnings on Wednesday

ADMA Biologics (NASDAQ:ADMA) will likely be posting its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect ADMA Biologics to post earnings of $0.16 per share and revenue of $131.20 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The company had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. During the same quarter in the previous year, the company posted $0.13 earnings per share. ADMA Biologics’s revenue was up 13.8% compared to the same quarter last year. On average, analysts expect ADMA Biologics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ADMA Biologics Stock Performance

Shares of ADMA opened at $15.37 on Tuesday. The firm has a market capitalization of $3.67 billion, a P/E ratio of 17.87 and a beta of 0.47. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The business has a fifty day moving average of $15.58 and a 200 day moving average of $18.01. ADMA Biologics has a one year low of $13.50 and a one year high of $25.67.

Hedge Funds Weigh In On ADMA Biologics

A number of hedge funds have recently made changes to their positions in ADMA. EverSource Wealth Advisors LLC boosted its stake in shares of ADMA Biologics by 385.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 2,180 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of ADMA Biologics by 28.9% in the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock worth $57,000 after buying an additional 700 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in shares of ADMA Biologics in the first quarter worth about $217,000. Tower Research Capital LLC TRC lifted its position in shares of ADMA Biologics by 279.5% in the second quarter. Tower Research Capital LLC TRC now owns 18,029 shares of the biotechnology company’s stock worth $328,000 after buying an additional 13,278 shares in the last quarter. Finally, HUB Investment Partners LLC raised its position in ADMA Biologics by 18.5% during the second quarter. HUB Investment Partners LLC now owns 18,560 shares of the biotechnology company’s stock valued at $338,000 after purchasing an additional 2,892 shares during the period. Institutional investors own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $27.67.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.